Association of matrix metalloproteinase 9 genotypes and cardiovascular disease risk factors with serum matrix metalloproteinase 9 concentrations in Taiwanese individuals

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 4, 2010, Pages 543-549

  Wu, Semon ^a,b   Hsu, Lung An ^c,d   Teng, Ming Sheng ^a   Lin, Jeng Feng ^a   Chang, Hsien Hsun ^a   Chang, Pi Yueh ^c   Hu, Chiao Feng ^c   Ko, Yu Lin ^a,e  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b CHINESE CULTURE UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Cardiovascular risk factors; Metalloproteinases; Polymorphism

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; GELATINASE B; GLUCOSE; INSULIN; SERUM AMYLOID A; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; FIBRINOGEN BLOOD LEVEL; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TAIWAN;

ADULT; AGE FACTORS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; FEMALE; FIBRINOGEN; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SMOKING; TAIWAN;

EID: 77949855128     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.099     Document Type: Article

References (35)

1. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-21494
2. Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res 2006;69:625-635
3. Sluijter JP, de Kleijn DP, Pasterkamp G. Vascular remodeling and protease inhibition - bench to bedside. Cardiovasc Res 2006;69:595-603.
4. Messerli FH. TIMPs, MMPs and cardiovascular disease. Eur Heart J 2004;25:1475-1476
5. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368-372
6. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001;141:211-217
7. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-1585
8. Nakamura T, Ebihara I, Shimada N, Koide H. Effect of cigarette smoking on plasma metalloproteinase-9 concentration. Clin Chim Acta 1998;276:173-177
9. Kalela A, Pönniö M, Koivu TA, Höyhtyä M, Huhtala H, Sillanaukee P, et al. Association of serum sialic acid and MMP-9 with lipids and inflammatory markers. Eur J Clin Invest 2000; 30:99-104.
10. Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase- 1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 2000;75:43-47
11. Sundström J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, et al. Relations of plasma matrix metalloproteinase- 9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 2004;109:2850-2856
12. Tayebjee MH, Lip GY, Blann AD, Macfadyen RJ. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb Res 2005;115:205-210
13. Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:372.
14. Derosa G, D'Angelo A, Scalise F, Avanzini MA, Tinelli C, Peros E, et al. Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart Vessels 2007;22:361-370
15. Derosa G, D'Angelo A, Tinelli C, Devangelio E, Consoli A, Miccoli R, et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab 2007;33:129-134
16. Demacq C, de Souza AP, Machado AA, Gerlach RF, Tanus- Santos JE. Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin Chim Acta 2006;365:183-187
17. Demacq C, Vasconcellos VB, Marcaccini AM, Gerlach RF, Silva WA Jr, Tanus-Santos JE. Functional polymorphisms in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects. Clin Chem Lab Med 2008;46:57-63.
18. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998;18: 1671-1678
19. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-684
20. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003;23:283-288
21. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004;27:1182-1186
22. Wu TL, Tsao KC, Chang CP, Li CN, Sun CF, Wu JT. Development of ELISA on microplate for serum C-reactive protein and establishment of age-dependent normal reference range. Clin Chim Acta 2002;322:163-168
23. Chan EC, Chang PY, Wu TL, Wu JT. Enzymatic assay of homocysteine on microtiter plate or a TECAN analyzer using crude lysate containing recombinant methionine gamma-lyase. Ann Clin Lab Sci 2005;35:155-160
24. Wu TL, Chen Tsai I, Chang PY, Tsao KC, Sun CF, Wu LL, et al. Establishment of an in-house ELISA and the reference range for serum amyloid A (SAA): complementarity between SAA and C-reactive protein as markers of inflammation. Clin Chim Acta 2007;376:72-76
25. Ko YL, Hsu LA, Hsu KH, Ko YH, Lee YS. The interactive effects of hepatic lipase gene promoter polymorphisms with sex and obesity on high-density- lipoprotein cholesterol levels in Taiwanese-Chinese. Atherosclerosis 2004;172:135-142
26. Hsu LA, Ko YL, Hsu KH, Ko YH, Lee YS. Genetic variations in the cholesteryl ester transfer protein gene and high density lipoprotein cholesterol levels in Taiwanese Chinese. Hum Genet 2002;110:57-63.
27. Vikman P, Xu CB, Edvinsson L. Lipid-soluble cigarette smoking particles induce expression of inflammatory and extracellular- matrix-related genes in rat cerebral arteries. Vasc Health Risk Manag 2009;5:333-341
28. Death AK, Fisher EJ, McGrath KC, Yue DK. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 2003;168:263-269
29. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006;113:2089-2096
30. Głowińska-Olzewska B, Urban M. Elevated matrix metallopro teinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents. Metabolism 2007;56:799-805.
31. Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999;99:1788-1794
32. Cha H, Kopetzki E, Huber R, Lanzendörfer M, Brandstetter H. Structural basis of the adaptive molecular recognition by MMP9. J Mol Biol 2002;320:1065-1079
33. Armstrong C, Abilleira S, Sitzer M, Markus HS, Bevan S. Polymorphisms in MMP family and TIMP genes and carotid artery intima-media thickness. Stroke 2007;38:2895-2899
34. Gerlach RF, Demacq C, Jung K, Tanus-Santos JE. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 2007;40:119-123
35. Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 2005;344:147-149